A Phase 2, Multicenter, Single-Arm, Study to Evaluate the Efficacy and Safety of Single-Agent Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Subjects With Mantle Cell Lymphoma Who Progress After Bortezomib Therapy
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 120
- 主要终点
- Overall response rate
研究概览
简要总结
The purpose of this study is to evaluate the efficacy and safety of ibrutinib in patients with mantle cell lymphoma who received at least 1 prior rituximab-containing chemotherapy regimen and who progressed after bortezomib therapy.
详细描述
This is a single-arm (all patients will receive the study drug) study to evaluate the efficacy and safety of ibrutinib in patients with mantle cell lymphoma (MCL) who have received at least 1 rituximab-containing chemotherapy regimen and who progressed after bortezomib therapy. Approximately 110 eligible patients will be enrolled. During the treatment phase, patients will receive 560 mg of ibrutinib by mouth once daily continuously until disease progression, unacceptable toxicity, or study end, whichever occurs first. Treatment will be continuous (without interruption) and self-administered at home. Doses can be held or reduced based on the severity of and the recovery from side effects of the study drug. The sponsor will ensure that patients benefiting from treatment with ibrutinib will be able to continue treatment after the end of the study. Data will be collected on disease response to the treatment, on progression-free survival, overall survival, and subsequent anti-MCL therapies. Serial pharmacokinetic (study of what the body does to a drug) samples will be collected as detailed in the protocol. Safety will be monitored throughout the study. An interim analysis of the pharmacokinetic data will occur approximately 3 months after the scheduled pharmacokinetic sampling in Cycles 1 and 2 has been completed. Data will be analyzed 1 year after the last patient is enrolled for the primary analysis and 2 years after last patient is enrolled for the final follow-up.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Diagnosis of confirmed mantle cell lymphoma (MCL) with at least 1 measurable site of disease according to Revised Response Criteria for Malignant Lymphoma
- •Must have received at least 1 prior rituximab-containing chemotherapy regimen, but no more than 5 prior regimens
- •Must have received at least 2 cycles of bortezomib therapy (single-agent or in combination) and have documented progressive disease during or after bortezomib therapy
- •Eastern Cooperative Oncology Group performance status score 0, 1, or 2
- •Hematology and biochemical values within protocol-defined parameters
排除标准
- •Prior chemotherapy within 3 weeks, nitrosoureas within 6 weeks, therapeutic anticancer antibodies within 4 weeks, radio- or toxin-immunoconjugates within 10 weeks, radiation therapy or other investigational agents within 3 weeks, or major surgery within 4 weeks of the first dose of study drug
- •Prior treatment with ibrutinib or other Bruton's tyrosine kinase inhibitors
- •More than 5 prior lines of therapy (separate lines of therapy are defined as single or combination therapies that are either separated by disease progression or by a >6 month treatment-free interval
- •Known central nervous system lymphoma
- •Diagnosed or treated for malignancy other than MCL, except malignancy treated with curative intent and with no known active disease present for >=3 years before the first dose of study drug and felt to be at low risk for recurrence by the treating physician, adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease, or adequately treated cervical carcinoma in situ without evidence of disease.
- •History of stroke or intracranial hemorrhage within 6 months prior to the first dose of study drug
- •Requires anticoagulation with warfarin or equivalent vitamin K antagonists
- •Requires treatment with strong CYP3A4/5 inhibitors
- •Clinically significant cardiovascular disease such as uncontrolled or symptomatic arrhythmias, congestive heart failure, or myocardial infarction within 6 months of Screening, or any Class 3 (moderate) or Class 4 (severe) cardiac disease as defined by the New York Heart Association Functional Classification
- •Known history of human immunodeficiency virus or active infection with hepatitis C virus or hepatitis B virus or any uncontrolled active systemic infection
- •Any life-threatening illness, medical condition, or organ system dysfunction which, in the investigator's opinion, could compromise the patient's safety, interfere with the absorption or metabolism of ibrutinib capsules, or put the study outcomes at undue risk
研究组 & 干预措施
Ibrutinib
干预措施: Ibrutinib (Drug)
结局指标
主要结局
Overall response rate
时间窗: 1 year after the last patient is enrolled
次要结局
- Overall survival rate(1 year after the last patient is enrolled and 2 years after the last patient is enrolled)
- Progression-free survival rate(1 year after the last patient is enrolled and 2 years after the last patient is enrolled)
- Mean change from baseline in the Lym subscale(1 year after the last patient is enrolled and 2 years after the last patient is enrolled)
- Mean change from baseline in the EQ-5D-5L index(1 year after the last patient is enrolled and 2 years after the last patient is enrolled)
- Mean plasma concentrations of ibrutinib(Up to Cycle 2, Day 21)
- Maximum observed plasma concentration of ibrutinib(Up to Cycle 2, Day 21)
- Minimum observed plasma concentration of ibrutinib(Up to Cycle 2, Day 21)
- Area under the plasma concentration-time curve from time 0 to 24 hours of ibrutinib(Up to Cycle 2, Day 21)
- The number of participants affected by an adverse event(Up to 30 days after the last dose of study medication)
- Overall response rate(1 year after the last patient is enrolled and 2 years after the last patient is enrolled)